Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: a randomized controlled trial.

JHEP reports : innovation in hepatology·2026
Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026
Same author

The thyroid-liver axis in MASLD: From metabolic control to clinical translation.

Med (New York, N.Y.)·2026
Same author

Risk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope.

Diabetes & metabolism·2026
Same author

Editorial: Refining the Natural History of MASLD by Imaging-Based Markers: The GOLDMINE Study.

Alimentary pharmacology & therapeutics·2026
Same author

Kidney biopsy findings in patients with obesity exhibit a wide spectrum of disease entities.

Clinical kidney journal·2026
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis.

Angelo Armandi1, Elisabetta Bugianesi2, Rohit Loomba3

  • 1Department of Medical Sciences, University of Turin, Turin, Italy. Electronic address: https://twitter.com/AngeloArmandi.

Clinics in Liver Disease
|May 16, 2026
PubMed
Summary
This summary is machine-generated.

Early identification of metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis is crucial. This review examines noninvasive screening algorithms for MASH, evidence, and implementation barriers to improve patient care.

Keywords:
Enhanced fibrosis testFIB-4FibrosisHepatocellular carcinomaMetabolic dysfunction-associated steatotic liver diseaseMetabolic syndromeNoninvasive testsVibration-controlled transient elastography

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Related Experiment Videos

Last Updated: May 18, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (≥F2) requires early detection to prevent severe liver and non-liver complications.
  • Current guidelines advocate for noninvasive screening of high-risk populations using multi-step algorithms.

Purpose of the Study:

  • To review MASH risk stratification algorithms.
  • To summarize supporting evidence and potential patient management benefits.
  • To discuss implementation barriers in clinical practice.

Main Methods:

  • Literature review of international guidelines and clinical studies.
  • Analysis of noninvasive testing algorithms for MASH and fibrosis.
  • Synthesis of evidence on clinical utility and implementation challenges.

Main Results:

  • Noninvasive algorithms are recommended for MASH screening in at-risk individuals.
  • Evidence supports the clinical utility of these algorithms for risk stratification.
  • Barriers to routine implementation in clinical practice exist and require addressing.

Conclusions:

  • Early MASH and fibrosis detection via noninvasive algorithms is vital for patient management.
  • Optimizing screening strategies can improve outcomes and reduce complications.
  • Overcoming implementation barriers is key to widespread adoption and improved patient care.